🇯🇵June 5, 2026·6d agoIndustry

Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Showing VOYXACT® (sibeprenlimab-szsi) Preserved Kidney Function Over 12 Months in IgA Nephropathy (IgAN)

Publisher

Otsuka Pharmaceutical

Japan

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

At a glance

Publisher: Otsuka Pharmaceutical
Region: Japan
Scope: Industry
Published: June 5, 2026

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Source route

Continue on otsuka.co.jp

Leave the platform to read the original full article on the publisher site.

Source: Otsuka Pharmaceutical

Scope: Industry

Open original article

Related coverage

More related coverage

Merck & Co. (MSD) News·4h ago

Merck Animal Health to Acquire TARGAN

Roche Newsroom·10h ago

FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer

Natco Pharma·15h ago

natco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26